| HOME >> BIOLOGY >> TECHNOLOGY |
About Tissue Regeneration Therapeutics
TRT is a private, Canadian life sciences company that exclusively licensed HUCPVC technology from the University of Toronto. TRT's business model involves licensing HUCPVC technology to national Cord Blood Banks seeking to offer new families a mesenchymal stem cell product in addition to their existing cord blood storage. In June 2006, TRT exclusively licensed rights for the Canadian market to CReATe Cord Blood Bank in Toronto, who market HUCPVCs as Peristem(TM). In June 2007, TRT licensed exclusive USA rights for HUCPVC technology for familial banking to Stem Cell Authority, Akron OH. TRT's preclinical and clinical development program is designed to define patient benefits for auto-immune and inflammatory diseases. For more information please visit http://www.verypowerfulbiology.com.
About BioLife Solutions
BioLife Solutions develops, manufactures and markets patented
hypothermic storage and cryopreservation solutions for cells, tissues, and
organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM)
platform of solutions are marketed to academic and commercial organizations
involved in cell therapy, tissue engineering, cord blood banking, drug
discovery, and toxicology testing. BioLife's products are serum-free and
protein-free, fully defined, and are formulated to reduce or prevent
preservation-induced, delayed-onset cell damage and death. BioLife's
enabling technology provides academic and clinical researchers significant
improvements in p
'/>"/>
| SOURCE BioLife Solutions Inc. Copyright©2007 PR Newswire. All rights reserved |